AMA adopts strategy for coverage of new genetic tests, therapeutics

| 3 Min Read

Physicians want greater transparency and standardization among payer coverage determinations

HONOLULU — To improve patient access to useful new genetic tests and therapeutics that have clinical impact, physicians gathered at the Interim Meeting of the American Medical Association (AMA) voted today to encourage the development of a comprehensive strategy that facilitates more consistent coverage of genetic/genomic tests and precision medicine.

“Precision medicine tests, technologies and therapeutics are increasingly being adopted into clinical practice as evidence of their effectiveness grows,” said AMA Board Member William E. Kobler, M.D. “However, many patients do not have access to precision medicine because most public and private health insurers do not offer coverage for genetic or genomic services unless certain clinical criteria and evidentiary standards are met. As a result, access to this next generation of clinical testing services is often limited.”

Full press release available when you sign in

Sign in to the AMA website to get the full version of this press release. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Man power walking or jogging, with dumbbells

New changes expand diabetes-prevention for more Medicare patients

| 3 Min Read
Three healthcare workers in discussion

AMA Joy in Medicine points the way to better care

| 5 Min Read
Doctors hold up magnifying glasses over a giant pancreas

Beyond watch and wait: Taking aim at pancreatic cysts

| 7 Min Read
Philip Kuriakose, MD, featured on "Health vs. Hype" AMA podcast

5 things patients should know about microplastics

| 8 Min Read